Developments in the therapeutic applications of bisphosphonates
- PMID: 10392318
- DOI: 10.1177/00912709922008272
Developments in the therapeutic applications of bisphosphonates
Abstract
The authors review the structural, pharmacologic, and clinical aspects of bisphosphonates, a class of drugs currently used to treat several disorders of bone and calcium metabolism. Pertinent literature on the bisphosphonates was reviewed with the help of a MEDLINE search and several bibliographies, including published clinical trials, monographs, and review articles. The bisphosphonates are analogs of pyrophosphate that, when given orally or intravenously, bind avidly to exposed bone mineral and disrupt bone turnover. These agents comprise three groups or generations, based on their potency and chemical structures. All three generations are effective in treating hypercalcemia, Paget's disease of bone, osteoporosis, and other disorders of accelerated bone turnover. The third-generation agents have the greatest potency and offer the promise of a convenient way to suppress or prevent osseous metastasis in patients with certain malignancies. As a group, these agents are well tolerated and, when administered correctly, rarely cause toxicity. The bisphosphonates are safe and effective agents for the treatment of disorders of accelerated bone turnover.
Similar articles
-
[Bisphosphonates: indications in bone diseases other than osteoporosis].Tunis Med. 2011 Jun;89(6):511-6. Tunis Med. 2011. PMID: 21681711 Review. French.
-
Bisphosphonates and the treatment of bone disease in the elderly.Drugs Aging. 1996 Feb;8(2):113-26. doi: 10.2165/00002512-199608020-00005. Drugs Aging. 1996. PMID: 8845585 Review.
-
The pharmacology of bisphosphonates and new insights into their mechanisms of action.J Bone Miner Res. 1999 Oct;14 Suppl 2:53-65. doi: 10.1002/jbmr.5650140212. J Bone Miner Res. 1999. PMID: 10510215 Review.
-
Bisphosphonates in bone diseases.Pharm World Sci. 1998 Oct;20(5):206-13. doi: 10.1023/a:1008626026484. Pharm World Sci. 1998. PMID: 9820883 Review.
-
Bisphosphonates: from grandparents to grandchildren.Clin Pediatr (Phila). 1999 Dec;38(12):687-702. doi: 10.1177/000992289903801201. Clin Pediatr (Phila). 1999. PMID: 10618761 Review.
Cited by
-
Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.Eukaryot Cell. 2006 Jul;5(7):1057-64. doi: 10.1128/EC.00034-06. Eukaryot Cell. 2006. PMID: 16835450 Free PMC article.
-
Neridronate inhibits angiogenesis in vitro and in vivo.Clin Rheumatol. 2007 Jul;26(7):1094-8. doi: 10.1007/s10067-006-0455-3. Epub 2006 Nov 15. Clin Rheumatol. 2007. PMID: 17106617
-
Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.J Mol Histol. 2015 Jun;46(3):313-23. doi: 10.1007/s10735-015-9620-9. Epub 2015 May 13. J Mol Histol. 2015. PMID: 25969354
-
New insights into short-chain prenyltransferases: structural features, evolutionary history and potential for selective inhibition.Cell Mol Life Sci. 2009 Dec;66(23):3685-95. doi: 10.1007/s00018-009-0100-9. Epub 2009 Jul 26. Cell Mol Life Sci. 2009. PMID: 19633972 Free PMC article. Review.
-
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.Am J Pathol. 2004 Dec;165(6):1865-74. doi: 10.1016/s0002-9440(10)63239-7. Am J Pathol. 2004. PMID: 15579431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials